Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR | MarketsandMarkets
The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR | MarketsandMarkets™
The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...
Kepler Capital Remains a Hold on Novo Nordisk (0QIU)
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on February 5 and set a price target of ...
Lilly Forecasts 2025 Profit Largely Above Estimates on Weight-Loss Drug Strength
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets.
Novo Nordisk sees sales surge
The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.
Novo Nordisk Says It's Not Immune to Potential Trump Tariffs, but Business Is Well-Positioned
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...